First-line Single-agent Regorafenib in Frail Patients with Metastatic Colorectal Cancer: a Pilot Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Jun 5

PMID 31159765

Citations 8

Authors

A Carrato

M Benavides

B Massuti

R Ferreiro-Monteagudo

P Garcia Alfonso

E Falco

M Reboredo

T Cano

J Gallego

J M Vieitez

L Layos

A Salud

E Polo

E Dotor

G Duran-Ogalla

M Rodriguez-Garrote

A Calvo

E Grande

E Aranda

Affiliations

Soon will be listed here.

Abstract

Background: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC.

Methods: Frail patients without prior advanced colorectal cancer treatment were included in the study. Definition of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or geriatric features.

Main Objective: to assess progression-free survival (PFS) rate at 6 months. Treatment consisted of 28-day cycles of orally administered regorafenib 160 mg/day (3 weeks followed by 1 week rest).

Results: Forty-seven patients were included in the study. Median age was 81 years (range 63-89). Frailty criteria: dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS rate at 6 months was 45% (95% confidence interval [CI] 30-60]. Median PFS was 5.6 months (95%CI 2.7-8.4). Median overall survival (OS) was 16 months (95%CI 7.8-24). Complete response, partial response and stable disease were observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-nine patients (83%) experienced grade 3-4 adverse events (AEs). The most common grade 3-4 AEs were hypertension (15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%). There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was required in 26 patients (55%) and dose-delays in 13 patients (28%).

Conclusions: The study did not meet the pre-specified boundary of 55% PFS rate at 6 months. Toxicity observed (83% patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate and overall survival results are interesting and might warrant further investigation to identify those who benefit from this approach.

Trial Registration: This trial was prospectively registered at EudraCT ( 2013-000236-94 ). Date of trial registration: April 9th, 2013.

Citing Articles

Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study.

Wang X, Bai Z, Deng W, Wang X Invest New Drugs. 2025; .

PMID: 39945972 DOI: 10.1007/s10637-025-01510-1.

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.

Adenis A, Ghiringhelli F, Gauthier L, Mazard T, Evesque L, Evrard A Cancer Chemother Pharmacol. 2024; 94(3):443-452.

PMID: 38987363 PMC: 11420384. DOI: 10.1007/s00280-024-04682-4.

Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.

Zheng E, Wlodarczyk M, Wegiel A, Osielczak A, Mozdzan M, Biskup L Front Surg. 2024; 11:1398289.

PMID: 38948479 PMC: 11211389. DOI: 10.3389/fsurg.2024.1398289.

Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature.

Bellia M, Sofia C, Marino M, Mazzeo C, Biondo S, Cucinotta E Radiol Case Rep. 2024; 19(5):2013-2019.

PMID: 38449482 PMC: 10917637. DOI: 10.1016/j.radcr.2024.02.018.

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.

Rong X, Liu H, Yu H, Zhao J, Wang J, Wang Y Invest New Drugs. 2022; 40(2):340-348.

PMID: 34997351 PMC: 8993747. DOI: 10.1007/s10637-021-01205-3.

References

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D . Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077-1085. DOI: 10.1016/S1470-2045(13)70154-2. View

Adenis A, De La Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J . Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016; 16:412. PMC: 4936193. DOI: 10.1186/s12885-016-2440-9. View

Sastre J, Massuti B, Pulido G, Guillen-Ponce C, Benavides M, Manzano J . First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer. 2015; 51(11):1371-80. DOI: 10.1016/j.ejca.2015.04.013. View

Aparicio T, Lavau-Denes S, Phelip J, Maillard E, Jouve J, Gargot D . Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2015; 27(1):121-7. DOI: 10.1093/annonc/mdv491. View

Argiles G, Saunders M, Rivera F, Sobrero A, Benson 3rd A, Guillen Ponce C . Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Eur J Cancer. 2015; 51(8):942-9. DOI: 10.1016/j.ejca.2015.02.013. View

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

Lang P, Michel J, Zekry D . Frailty syndrome: a transitional state in a dynamic process. Gerontology. 2009; 55(5):539-49. DOI: 10.1159/000211949. View

Davis S, Eckhardt S, Messersmith W, Jimeno A . The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc). 2013; 49(2):105-15. DOI: 10.1358/dot.2013.49.2.1930525. View

Huisingh-Scheetz M, Walston J . How should older adults with cancer be evaluated for frailty?. J Geriatr Oncol. 2016; 8(1):8-15. PMC: 5161734. DOI: 10.1016/j.jgo.2016.06.003. View

10.

Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Reglat A, Pariente A . Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database. Target Oncol. 2017; 12(6):805-814. DOI: 10.1007/s11523-017-0529-y. View

11.

Li J, Qin S, Xu R, Yau T, Ma B, Pan H . Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015; 16(6):619-29. DOI: 10.1016/S1470-2045(15)70156-7. View

12.

Gutierrez M, Kummar S, Giaccone G . Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol. 2009; 6(5):259-65. PMC: 7079165. DOI: 10.1038/nrclinonc.2009.38. View

13.

Tabernero J, Lenz H, Siena S, Sobrero A, Falcone A, Ychou M . Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015; 16(8):937-48. PMC: 7513622. DOI: 10.1016/S1470-2045(15)00138-2. View

14.

van der Pool A, Damhuis R, IJzermans J, de Wilt J, Eggermont A, Kranse R . Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2010; 14(1):56-61. DOI: 10.1111/j.1463-1318.2010.02539.x. View

15.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

16.

Ommundsen N, Wyller T, Nesbakken A, Jordhoy M, Bakka A, Skovlund E . Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist. 2014; 19(12):1268-75. PMC: 4257747. DOI: 10.1634/theoncologist.2014-0237. View

17.

Sastre J, Gravalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E . First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist. 2012; 17(3):339-45. PMC: 3316919. DOI: 10.1634/theoncologist.2011-0406. View

18.

van der Geest L, Lam-Boer J, Koopman M, Verhoef C, Elferink M, de Wilt J . Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015; 32(5):457-65. DOI: 10.1007/s10585-015-9719-0. View

19.

Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker U, Kohne C . Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013; 24(6):1560-7. PMC: 3660081. DOI: 10.1093/annonc/mdt056. View

20.

Hofheinz R, Arnold D, Kubicka S, Prasnikar N, Vogel A . Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat. 2015; 38(6):300-8. DOI: 10.1159/000382067. View